Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population

被引：15

作者：

Veceric-Haler, Zeljka ^{[1
]}

Romozi, Karmen ^{[1
]}

Antonic, Manja ^{[1
]}

Benedik, Miha ^{[1
]}

Ponikvar, Jadranka Buturovic ^{[1
]}

Ponikvar, Rafael ^{[1
]}

Knap, Bojan ^{[1
]}

机构：

[1] Univ Med Ctr Ljubljana, Dept Nephrol, Ljubljana 1525, Slovenia

来源：

THERAPEUTIC APHERESIS AND DIALYSIS | 2016年 / 20卷 / 03期

关键词：

Calcitriol; Hemodialysis; Paricalcitol; Secondary hyperparathyroidism; HEMODIALYSIS-PATIENTS; MORTALITY RISK; LONG-TERM; CALCIUM; PHOSPHORUS; EFFICACY; OUTCOMES; CAPSULE; STAGE-3; DISEASE;

D O I：

10.1111/1744-9987.12434

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Management of secondary hyperparathyroidism (SHPT) in dialysis population includes the use of active vitamin D forms, among which paricalcitol was shown to be more effective at reducing parathyroid hormone (PTH) concentrations. A prospective randomized study comparing the effectiveness and safety of peroral paricalcitol and calcitriol in suppressing PTH concentrations in 20 hemodialysis patients was performed comparing the influence of agents on PTH suppression, calcium (Ca) and phosphate (P) level and calcium-phosphorus product (CxP). The study was performed in an intent to treat manner with primary end point in reduction of PTH level in the target area of 150>PTH<300 ng/L after 3 months. At the time point 3 months after therapy induction paricalcitol and calcitriol were equally efficient at correcting PTH levels, with paricalcitol showing significantly less calcemic effect than calcitriol.

引用

页码：261 / 266

页数：6

共 28 条

[1] A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4 [J].

Abboud, H ;

Coyne, D ;

Smolenski, O ;

Anger, M ;

Lunde, N ;

Qiu, P ;

Hippensteel, R ;

Pradhan, RS ;

Palaparthy, RV ;

Kavanaugh, A ;

Melnick, JZ ;

Williams, LA ;

Batlle, D .

AMERICAN JOURNAL OF NEPHROLOGY, 2006, 26 (01) :105-114

[2] Nonclassical aspects of differential vitamin D receptor activation [J].

Andress, Dennis .

DRUGS, 2007, 67 (14) :1999-2012

[3]

Benedik M, 2004, DIALIZNO ZDAVLJENJE, P255

[4] Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].

Block, GA ;

Klassen, PS ;

Lazarus, JM ;

Ofsthun, N ;

Lowrie, EG ;

Chertow, GM .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218

[5] Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphate transport [J].

Brown, AJ ;

Finch, J ;

Slatopolsky, E .

JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2002, 139 (05) :279-284

[6]

Brown Alex J, 2002, Treat Endocrinol, V1, P313, DOI 10.2165/00024677-200201050-00004

[7] New insights into the mechanisms of vitamin D action [J].

Christakos, S ;

Dhawan, P ;

Liu, Y ;

Peng, XR ;

Porta, A .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 88 (04) :695-705

[8] Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD [J].

Coyne, D ;

Acharya, M ;

Qiu, P ;

Abboud, H ;

Batlle, D ;

Rosansky, S ;

Fadem, S ;

Levine, B ;

Williams, L ;

Andress, DL ;

Sprague, SM .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (02) :263-276

[9] Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings [J].

Dobrez, DG ;

Mathes, A ;

Amdahl, M ;

Marx, SE ;

Melnick, JZ ;

Sprague, SM .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (05) :1174-1181

[10] VITAMIN D METABOLISM AND VITAMIN D TRADITIONAL AND NONTRADITIONAL, TARGET ORGANS: IMPLICATIONS FOR KIDNEY PATIENTS [J].

Dusilova-Sulkova, Sylvie .

JOURNAL OF RENAL CARE, 2009, 35 :39-44

← 1 2 3 →